Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis-Reference-Cited by-同舟云学术

Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis

Published:2016-06-17 Issue:19 Volume:122 Page:3005-3014
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Deol Abhinav¹,Sengsayadeth Salyka²,Ahn Kwang Woo³⁴,Wang Hai-Lin³,Aljurf Mahmoud⁵,Antin Joseph Harry⁶,Battiwalla Minoo⁷,Bornhauser Martin⁸,Cahn Jean-Yves⁹,Camitta Bruce¹⁰,Chen Yi-Bin¹¹,Cutler Corey S.⁶,Gale Robert Peter¹²,Ganguly Siddhartha¹³,Hamadani Mehdi³,Inamoto Yoshihiro¹⁴,Jagasia Madan²,Kamble Rammurti¹⁵,Koreth John⁶,Lazarus Hillard M.¹⁶,Liesveld Jane¹⁷,Litzow Mark R.¹⁸,Marks David I.¹⁹,Nishihori Taiga²⁰,Olsson Richard F.²¹²²,Reshef Ran²³,Rowe Jacob M.²⁴,Saad Ayman A.²⁵,Sabloff Mitchell²⁶,Schouten Harry C.²⁷,Shea Thomas C.²⁸,Soiffer Robert J.⁶,Uy Geoffrey L.²⁹,Waller Edmond K.³⁰,Wiernik Peter H.³¹,Wirk Baldeep³²,Woolfrey Ann E.³³,Bunjes Donald³⁴,Devine Steven³⁵,de Lima Marcos³⁶,Sandmaier Brenda M.³⁷,Weisdorf Dan³⁸,Khoury Hanna Jean³⁰,Saber Wael³

Affiliation:

1. Department of Oncology, Karmanos Cancer Institute; Wayne State University; Detroit Michigan

2. Vanderbilt University Medical Center; Nashville Tennessee

3. Department of Medicine, Center for International Blood and Marrow Transplant Research; Medical College of Wisconsin; Milwaukee Wisconsin

4. Division of Biostatistics, Institute for Health and Society; Medical College of Wisconsin; Milwaukee Wisconsin

5. Department of Oncology; King Faisal Specialist Hospital Center and Research; Riyadh Saudi Arabia

6. Center for Hematologic Oncology, Department of Medical Oncology; Dana-Farber Cancer Institute; Boston Massachusetts

7. Hematology Branch, National Heart, Lung, and Blood Institute; Bethesda Maryland

8. Carl Gustav Carus University Hospital; Dresden Germany

9. Department of Hematology; University Hospital; Grenoble France

10. Midwest Center for Cancer and Blood Disorders, Medical College of Wisconsin and Children's Hospital of Wisconsin; Milwaukee Wisconsin

11. Division of Hematology/Oncology; Massachusetts General Hospital; Boston Massachusetts

12. Hematology Research Center, Division of Experimental Medicine, Department of Medicine; Imperial College London; London United Kingdom

13. Blood and Marrow Transplantation, Division of Hematology and Oncology; University of Kansas Medical Center; Kansas City Kansas

14. Division of Hematopoietic Stem Cell Transplantation; National Cancer Center Hospital; Tokyo Japan

15. Division of Hematology and Oncology, Center for Cell and Gene Therapy; Baylor College of Medicine; Houston Texas

16. Seidman Cancer Center; University Hospitals Case Medical Center; Cleveland Ohio

17. Department of Medicine; University of Rochester Medical Center; Rochester New York

18. Division of Hematology and Transplant Center; Mayo Clinic-Rochester; Rochester New York

19. Pediatric Bone Marrow Transplant; University Hospitals Bristol National Health Service Trust; Bristol United Kingdom

20. Department of Blood and Marrow Transplantation; H. Lee Moffitt Cancer Center and Research Institute; Tampa Florida

21. Division of Therapeutic Immunology, Department of Laboratory Medicine; Karolinska Institute; Stockholm Sweden

22. Center for Clinical Research Sormland; Uppsala University; Uppsala Sweden

23. Blood and Marrow Transplantation Program and Columbia Center for Translational Immunology; Columbia University Medical Center; New York New York

24. Department of Hematology; Shaare Zedek Medical Center; Jerusalem Israel

25. Division of Hematology/Oncology, Department of Medicine; University of Alabama at Birmingham; Birmingham Alabama

26. Division of Hematology, Department of Medicine; University of Ottawa and Ottawa Hospital Research Institute; Ottawa Ontario Canada

27. Department of Hematology; Academy Hospital; Maastricht the Netherlands

28. Division of Hematology and Oncology, Department of Medicine; University of North Carolina Health Care; Chapel Hill North Carolina

29. Divsion of Oncology; Washington University School of Medicine; St Louis Missouri

30. Department of Hematology and Medical Oncology; Winship Cancer Institute, Emory University; Atlanta Georgia

31. Our Lady of Mercy Medical Center; Bronx New York

32. Division of Bone Marrow Transplant; Seattle Cancer Care Alliance; Seattle Washington

33. Fred Hutchinson Cancer Research Center; Seattle Washington

34. Department of Internal Medicine III; Ulm University Hospital; Ulm Germany

35. Department of Internal Medicine; The Ohio State University Comprehensive Cancer Center-James; Columbus Ohio

36. Department of Medicine, Seidman Cancer Center; University Hospitals Case Medical Center; Cleveland Ohio

37. Division of Medical Oncology; University of Washington and Clinical Research Division, Fred Hutchinson Cancer Research Center; Seattle Washington

38. Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match; Minneapolis Minnesota

Funder

Public Health Service

the National Cancer Institute (NCI)

the National Heart, Lung, and Blood Institute (NHLBI)

the National Institute of Allergy and Infectious Diseases (NIAID)

the NHLIB and the NCI

the Health Resources and Services Administration/Department of Health and Human Services

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference34 articles.

1. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia;Kiyoi;Blood,1999

2. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials;Kottaridis;Blood,2001

3. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm;Frohling;Blood,2002

4. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease;Schnittger;Blood,2002

5. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis;Thiede;Blood,2002

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITDmut+ Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the United States and Canada;Transplantation and Cellular Therapy;2024-07

2. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3;Journal of Clinical Oncology;2024-05-20

3. Targeting BMAL1 reverses drug resistance of acute myeloid leukemia cells and promotes ferroptosis through HMGB1-GPX4 signaling pathway;Journal of Cancer Research and Clinical Oncology;2024-05-04

4. Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation in children with FLT3-ITD mutated acute myeloid leukaemia;Bone Marrow Transplantation;2024-03-05

5. Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation in children with FLT3-ITD mutated acute myeloid leukaemia;2023-10-30